Overview

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Status:
Active, not recruiting

Trial end date:
2022-03-25

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.

Phase:

Phase 3

Details

Lead Sponsor:

Chugai Pharmaceutical
Hoffmann-La Roche

Collaborator:

Chugai Pharmaceutical